Catch me if you can.

As COVID-19 continually changes its face, the last therapeutic monoclonal antibody standing has lost its FDA approval as it failed to prove effective against today’s most common variants Omicron BQ.1 and BQ.11, leaving a handful of antivirals as the only therapies with lasting emergency authorizations for immunocompetent patients. | FDA 2022